Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

NARecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 13, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions
Adrenal Cortical CarcinomaMedullary Thyroid CancerThymic Neuroendocrine CarcinomaPancreatic Neuroendocrine Tumor
Interventions
BIOLOGICAL

individualized mRNA neoantigen vaccine (mRNA-0523-L001)

Individualized mRNA neoantigen vaccine (mRNA-0523-L001) will be injected intramuscularly every 21 days for 9 cycles. Dose escalation will be administered in 3 patients. 18 additional patients will be recruited and administered at the maximum tolerated(MTD) dose for all nine cycles.

Trial Locations (1)

200025

RECRUITING

Ruijin hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER